HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAsafety guidance72% confidence

FDA Alerts Health Care Providers to Cases of Neurologic Complications from General Anesthesia Linked to Genetic Variant in Patients of Maternal Venezuelan Ancestry

Source: FDA

Why This Matters

Why this matters: sets a safety guidance precedent in the same sub-indication (cardiology) as United Therapeutics.

Regulatory Analysis

Food and Drug Administration (FDA) is investigating the safety of sevoflurane and other general anesthetics based on published scientific reports of unexpected catastrophic outcomes, including severe neurologic adverse outcomes and death, occurring in adult and pediatric patients.

Supporting Context

Therapeutic area
Pulmonology · Pulmonary Hypertension
Sub-indication
Hypertension

Related signal: United Therapeutics' Ralinepag Shows Potential in Improving Exercise Capacity in PH Patients

Source

View source document

Related Signal

Open signal — United Therapeutics' Ralinepag Shows Potential in Improving Exercise Capacity in PH Patients
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.